Ticagrelor in Patients with Stable Coronary Disease and Diabetes
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to aspirin improves outcomes in this population is unclear. METHODS: In this randomized, double-blind trial, we assigned patients who were 50 years of age or older and who had stable coronary artery disease and type 2 diabetes mellitus to receive either ticagrelor plus aspirin or placebo plus aspirin. Patients with previous myocardial infarction or stroke were excluded. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety outcome was major bleeding as defined by the Thrombolysis in Myocardial Infarction (TIMI) criteria. RESULTS: A total of 19,220 patients underwent randomization. The median follow-up was 39.9 months. Permanent treatment discontinuation was more frequent with ticagrelor than placebo (34.5% vs. 25.4%). The incidence of ischemic cardiovascular events (the primary efficacy outcome) was lower in the ticagrelor group than in the placebo group (7.7% vs. 8.5%; hazard ratio, 0.90; 95% confidence interval [CI], 0.81 to 0.99; P = 0.04), whereas the incidence of TIMI major bleeding was higher (2.2% vs. 1.0%; hazard ratio, 2.32; 95% CI, 1.82 to 2.94; P<0.001), as was the incidence of intracranial hemorrhage (0.7% vs. 0.5%; hazard ratio, 1.71; 95% CI, 1.18 to 2.48; P = 0.005). There was no significant difference in the incidence of fatal bleeding (0.2% vs. 0.1%; hazard ratio, 1.90; 95% CI, 0.87 to 4.15; P = 0.11). The incidence of an exploratory composite outcome of irreversible harm (death from any cause, myocardial infarction, stroke, fatal bleeding, or intracranial hemorrhage) was similar in the ticagrelor group and the placebo group (10.1% vs. 10.8%; hazard ratio, 0.93; 95% CI, 0.86 to 1.02). CONCLUSIONS: In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin. (Funded by AstraZeneca; THEMIS ClinicalTrials.gov number, NCT01991795.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, the addition of ticagrelor to aspirin reduced the risk of ischemic cardiovascular events compared with aspirin alone in people with diabetes and stable coronary artery disease (201,202).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [201]
In the citing paper
“However, a higher incidence of major bleeding, including intracranial hemorrhage, was noted with dual antiplatelet therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [201]
In the citing paper
“Similarly, the addition of ticagrelor to aspirin reduced the risk of ischemic cardiovascular events compared with aspirin alone in people with diabetes and stable coronary artery disease (189,190).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [189]
In the citing paper
“Thus, an unfavourable benefit-risk profile is associated with adding ticagrelor to ASA in this setting.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [302]
In the citing paper
“Over a median 3.3 years of follow-up, the primary efficacy outcome of CV death, MI, or stroke showed a marginal 10% RR reduction by ticagrelor vs. placebo, while both Thrombolysis in Myocardial Infarction (TIMI) major and intracranial bleeding were significantly increased.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [302]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Self-citationLong-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Self-citationTwelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928
Self-citationPrasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Self-citationBhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.025 · Cited by 805
Self-citationVranckx, P., Valgimigli, M., Jüni, P., Hamm, C., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 791
Self-citation
Cited by
Items 301–365 of 365
Treatment Strategies in Patients with Diabetes Mellitus and Ischemic Heart Disease
Mahowald, M. K., Locker, C. L., Singh, M., & Frye, R. L. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch19
Implementation of Battlefield Advanced Trauma Life Support (BATLS) in the Danish Armed Forces
Jensen, C. T., Johansson, A., Emmertsen, N.-C., de Mello, W., & Lundberg, L. E. R. (2013) · Borås Academic Digital Archive (University of Borås)
(2021) · Elsevier eBooks · doi:10.1016/b978-3-437-23841-3.00041-2
Viswanathan, G. N., Harper, A. R., Badimón, J. J., Marshall, S. M., & Zaman, A. (2022) · medRxiv · doi:10.1101/2022.03.04.22271893
Balance of Ischemia and Bleeding in Selecting Intensity and Duration of Antithrombotic Regimens
Cao, D., Camaj, A., & Mehran, R. (2022) · Wiley eBooks · doi:10.1002/9781119697367.ch43
Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease
Capranzano, P., & Angiolillo, D. J. (2022) · Wiley eBooks · doi:10.1002/9781119697367.ch38
Ticagrelor: efficacy and safety in patients with diabetes
(2019) · Reactions Weekly · doi:10.1007/s40278-019-67446-9
Diagnosis and Management of Heart Disease
Stolker, J. M., & Rich, M. W. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108942751.013
Pollack, C. V., Steg, P. G., James, S. K., Jolly, S. S., Kosiborod, M., & Bonaca, M. P. (2022) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000292
Self-citationDiabetes und kardiovaskuläre Ereignisse: Ursache, Prävention und Therapie
Darius, H. (2022) · Diabetes aktuell · doi:10.1055/a-1879-9266
Kalashnikov, V. Y., & Michurova, M. S. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.10.201911
Le patient atteint de maladies cardiovasculaires
Gaboreau, Y., Vorilhon, P., Charuel, É., & Frappé, P. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-76710-4.00014-0
REACHing conclusions on the external applicability of the THEMIS into clinical practice
Gupta, R., & Mares, A. C. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.12.050
Adawi, N., Rotshild, V., Yanko, S., Mowaswes, M., Amir, O., Haitner, G., Matok, I., & Raccah, B. H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1016390
Zheng, N., Zhong, J., Chen, X., Su, J., Liu, C., & Jiang, L. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00574-9
Thrombozytenaggregationshemmung nach Koronarintervention (PCI)
Aidery, P., & Geisler, T. (2023) · Kardiologie up2date · doi:10.1055/a-1438-7394
Lee, S. H., Jeong, M. H., Ahn, J. H., Hyun, D. Y., Cho, K. H., Kim, M. C., Sim, D. S., Hong, Y. J., Kim, J. H., Ahn, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2681080/v1
Managing Stable Coronary Artery Disease in Diabetes
Koulouridis, I., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_23
The role of acetylsalicylic acid in the treatment of diseases caused by atherosclerosis
Yavelov, I. S. (2023) · Aterotromboz = Atherothrombosis · doi:10.21518/at2023-003
Beginning and Managing Underlying Comorbidities
Billah, Z., Chadnick, Z., Kansagra, K., Kimyaghalam, A., Madassery, S., Shinagawa, A., Singh, K., & Vatakencherry, G. (2023) · Springer eBooks · doi:10.1007/978-3-031-36480-8_4
Greco, A., & Capodanno, D. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0015
Pareek, M., & Bhatt, D. L. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0006
Self-citationXia, X., Chen, S., Cao, C., Ye, Y., & Shen, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-3930328/v1
Lemus-Barrios, G. A., España, J. B., Benavides, L., Cáceres-Méndez, E. A., & Peña, A. A. G. (2024) · Medical Research Archives · doi:10.18103/mra.v12i3.5107 · Cited by 1
Marinho, L. L. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2024.tde-25042024-113753
Xia, X., Chen, S., Cao, C., Ye, Y., & Shen, Y. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241254107
AVALIAÇÃO DO RISCO CARDIOVASCULAR E INTERVENÇÕES TERAPÊUTICAS NA DOENÇA ARTERIAL PERIFÉRICA
Nakasako, D. S., Oliveira, J. M., Fonseca, J. L. I., Silva, L. B. E., Clos, L. C. R., Martins, M. M., Fernandes, N. C. B., Bezerra, R. J. B., & Costa, R. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024479p595 · Cited by 1
Shnain, D. H., Mahmood, G. M., & Ahmed, S. O. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3970
Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials
Hogan, S. E., Canonico, M. E., King, R. W., Wang, C. C. L., Nehler, M. R., Parr, J., Rogers, R. K., Lu, W., Albanese, J., Barnathan, E. S., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101763
Arnreiter, M., von Scheidt, M., Albes, J. M., Attmann, T., Boening, A., Choi, Y., Conradi, L., Danner, B. C., Fach, A., Friedrich, I., et al. (2025) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaf175 · Cited by 1
Antithrombotische Therapie bei polyvaskulärer Atherosklerose
Espinola–Klein, C. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2359-4422
Prévention secondaire chez le coronarien
Sorbets, E. (2025) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(25)48213-1
Antithrombotic therapy after stent implantation. One size does not fit all
Morais, J. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2025.08.001
Prevención secundaria en el paciente coronario
Sorbets, E. (2025) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(25)51065-6
Shalaginova, Y. O., & Shakhnovich, R. M. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6482
Clinical Pharmacology of P2Y12 Receptor Inhibitors
Laudani, C., Capodanno, D., & Angiolillo, D. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_2
Santilli, F., & Simeone, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-96352-0_7
Willson, M. N., & McKeirnan, K. C. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch22
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Prevenzione secondaria nel paziente affetto da coronaropatia
Sorbets, E. (2025) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(25)51186-5
Rahaman, S. S., BISWAS, R. K., & Pal, A. (2025) · Amrita Journal of Medicine · doi:10.4103/amjm.amjm_20_25
Ploumen, E. H., Pinxterhuis, T. H., Zocca, P., Roguin, A., Anthonio, R. L., Schotborgh, C. E., Benit, E., Aminian, A., Danse, P. W., Doggen, C. J. M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16909683
Gao, C., Tomaniak, M., Takahashi, K., Kawashima, H., Wang, R., Hara, H., Ono, M., Montalescot, G., Garg, S., Haude, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13106528
Self-citationParker, W. A. E., Sagar, R. C., Kurdee, Z., Hawkins, F., Naseem, K. M., Grant, P. J., Storey, R. F., & Ajjan, R. A. (2021) · Figshare · doi:10.6084/m9.figshare.17273244
Asymptomatic Peripheral Arterial Disease and Intermittent Claudication: An Overview
Paciullo, F., Gresele, P., Parmar, G. M., & Catalano, M. M. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_29
Berg, D. D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00008-2
Role of Percutaneous Coronary Intervention in Patients With Diabetes
Gencer, B., Iglesias, J. F., & Roffi, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00021-5
Effect of Antithrombotic Therapy on Coronary Heart Disease Risk in People With Diabetes Mellitus
O’Donoghue, M., & Bhatt, D. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00020-3
Self-citationOliveira, J. R. C. D. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014177 · Cited by 1
Alqahtani, S. A., & AlQahatani, S. (2026) · Cureus · doi:10.7759/cureus.106088
Laino, A., Piccolo, R., Canonico, M. E., Avvedimento, M., Simonetti, F., Paolillo, R., Piaz, F. D., Charlier, B., Spinelli, A. M., Cristiano, S., et al. (2026) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-026-03385-2
Nedelcu, S. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00907
Liu, T., Chen, Z., Wang, R., Xu, X., Gao, F., Zu, J., Wang, Z., & Tian, Y. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07871-w
Alfehaid, L., Alzahrani, E., Alsubaie, A., Almutairi, M., Alomran, M., & Alghadeer, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083167
Selvarajah, A., Fabris, E., van Leeuwen, M. A. H., Hof, A. W. J. V. ’., & Hermanides, R. S. (2026) · TH Open · doi:10.1055/a-2859-7418
Valeriani, E., Marcucci, R., Nisio, M. D., Calabrò, P., Cirillo, P. L., Gresele, P., Patti, G., Pengo, V., Palumbo, I., Poli, D., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.05.016
Basit, A., Aslam, M. H., Anwar, M. M., Sarwar, M. A., Akram, A., Ismail, Q., Iftikhar, A., & Haq, M. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.115880
Kyaw, M. T., & Moe, A. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/3961611 · Cited by 1
麦, 麦. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662319
P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage
Jin, C., Song, Y., Grory, B. M., Sun, J., Alhanti, B., Fonarow, G. C., Schwamm, L. H., Sheth, K. N., Smith, E. E., Messe, S. R., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.22239
Self-citationAbounader, G., Bejjani, S., Chaaban, S. M., Dada, S., Fakhoury, R., Hamade, M., Hobeika, R., Iskandarani, M., Mohammed, M., Rebeiz, A., et al. (2026) · Cureus · doi:10.7759/cureus.112849
Abdelgader, M., Khalid, R., Yadav, K., Ahmed, S. E. S., Veerasamy, M., Das, A., & Bulluck, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51947
Shebankov, A. A., Lomakin, N. V., Zotova, I. V., Shirokov, E. A., & Sychev, D. A. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-7095
Fath, A. R., Rymer, J. A., Marks, A., WOJDYLA, D. M., Gilchrist, I. C., Sandoval, Y. B., Shah, B., Brilakis, E. S., Rao, S. V., & Elgendy, I. Y. (2026) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.126.016658
Metadata
- Authors
- Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., Leonsson-Zachrisson, M., Liu, Y., Opolski, G., Zateyshchikov, D., Ge, J., Nicolau, J. C., Corbalán, R., Cornel, J. H., Widimský, P., & Leiter, L. A.
- Affiliations
- From the French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Université de Paris, INSERM Unité 1148 (P.G.S.), Assistance Publique–Hôpitaux de Paris (P.G.S., T.S.), Hôpital Saint Antoine, Department of Clinical Pharmacology, Unité de Recherche Clinique (T.S.), and Sorbonne Université (T.S.) — all in Paris; the National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London (P.G.S., K.F.); Brigham and Women’s Hospital Heart and...
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Uppsala University (SE)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-03
- Volume
- 381
- Issue
- 14
- Pages
- 1309-1320
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2970797239
- Cited by
- 365
- References
- 32
- Citations by year
- 2026: 27 · 2025: 30 · 2024: 34 · 2023: 48 · 2022: 56 · 2021: 81 · 2020: 75 · 2019: 12
- FWCI
- 40.45
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Warwick Research Archive Portal (University of Warwick) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, stable coronary artery disease, type 2 diabetes, antiplatelet therapy, aspirin, major bleeding, intracranial hemorrhage, cardiovascular events, irreversible harm, treatment discontinuation, P2Y12 inhibitors, elderly patients, cardiovascular risk stratification, bleeding risk assessment, risk-benefit assessment
- MeSH terms
- Ticagrelor, Aged, Aspirin, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Incidence, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.